Impact of COVID-19 outbreak on patients with ST-segment elevation myocardial ınfarction (STEMI) in Turkey: results from TURSER study (TURKISH St-segment elevation myocardial ınfarction registry)

[1] Onder G(2020)Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy JAMA 323 1775-1776

[2] Rezza G(2020)Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era Eur Heart J 41 2083-2088

[3] Brusaferro S(2015)Relation between door-to balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study Lancet 385 1114-1122

[4] De Rosa S(2014)Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST segment elevation myocardia linfarction: the INFUSE-AMI trial (INFUSE anterior myocardial infarction) JACC Cardiovasc Interv 7 733-740

[5] Spaccarotella C(2020)COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up J Am Coll Cardiol 75 2950-2973

[6] Basso C(2020)High thrombus burden in patients with COVID-19 presenting with ST-elevation myocardial infarction J Am Coll Cardiol 41 2209-2216

[7] Nallamothu BK(2020)Clinical application of the 4th universal definition of myocardial ınfarction Eur Heart J 00 119-177

[8] Normand S-LT(2018)2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial in Eur Heart J 22 6B-14B

[9] Wang Y(2010)Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention J Invasive Cardiol 103 2550-2554

[10] Guerchicoff A(2001)Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation 69 140-146

[1] Onder G(2020)Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy JAMA 323 1775-1776

[2] Rezza G(2020)Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era Eur Heart J 41 2083-2088

[3] Brusaferro S(2015)Relation between door-to balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study Lancet 385 1114-1122

[4] De Rosa S(2014)Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST segment elevation myocardia linfarction: the INFUSE-AMI trial (INFUSE anterior myocardial infarction) JACC Cardiovasc Interv 7 733-740

[5] Spaccarotella C(2020)COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up J Am Coll Cardiol 75 2950-2973

[6] Basso C(2020)High thrombus burden in patients with COVID-19 presenting with ST-elevation myocardial infarction J Am Coll Cardiol 41 2209-2216

[7] Nallamothu BK(2020)Clinical application of the 4th universal definition of myocardial ınfarction Eur Heart J 00 119-177

[8] Normand S-LT(2018)2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial in Eur Heart J 22 6B-14B

[9] Wang Y(2010)Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention J Invasive Cardiol 103 2550-2554

[10] Guerchicoff A(2001)Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation 69 140-146